Valuation: Entrada Therapeutics, Inc.

Market Cap 218M 192M 178M 164M 307M 21.11B 313M 2.13B 831M 10.3B 818M 801M 35.72B P/E 2026 *
-1.5x
P/E 2027 * -1.59x
Enterprise Value 125M 110M 102M 93.57M 175M 12.06B 179M 1.22B 475M 5.88B 467M 457M 20.4B EV / Sales 2026 *
8.31x
EV / Sales 2027 * -3.81x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week-11.94%
Current month-17.80%
1 month-16.44%
3 months-52.77%
6 months-47.07%
Current year-41.15%
1 week 5.9
Extreme 5.9
6.91
1 month 5.9
Extreme 5.9
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 44 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Director

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%-11.94%-5.32%-64.54% 218M
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-1.43%+4.65%+29.65%-4.56% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-1.34%+5.88%+32.80%+545.36% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.13%-0.06%+37.41%+146.11% 24.22B
Weighted average by Cap. +1.26%+3.16%+43.36%+133.80%

Financials

2026 *2027 *
Net sales 14.99M 13.18M 12.25M 11.26M 21.12M 1.45B 21.5M 146M 57.12M 708M 56.27M 55.06M 2.46B 29.81M 26.22M 24.36M 22.4M 42.01M 2.89B 42.76M 291M 114M 1.41B 112M 109M 4.88B
Net income -176M -155M -144M -132M -248M -17.03B -252M -1.72B -670M -8.31B -660M -646M -28.82B -188M -165M -153M -141M -264M -18.17B -269M -1.83B -715M -8.86B -704M -689M -30.74B
Net Debt -93.49M -82.22M -76.38M -70.25M -132M -9.05B -134M -913M -356M -4.42B -351M -343M -15.32B -331M -292M -271M -249M -467M -32.1B -475M -3.24B -1.26B -15.66B -1.24B -1.22B -54.31B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
23/07/26 $6.050 -1.63% 791,911
22/07/26 $6.150 -4.80% 375,955
21/07/26 $6.460 +1.89% 513,746
20/07/26 $6.340 -7.98% 371,531
17/07/26 $6.890 +0.29% 378,187
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.050USD
Average target price
18.75USD
Spread / Average Target
+209.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock